Institute of Cybernetic Surgery Cyberknife
Institute of Cybernetic Surgery Cyberknife
Poland, Wieliszew
Melanoma treatment cost in Poland is influenced by the disease stage and required technology, with a consultation with an oncologist ranging from $100 to $100. Standard melanoma surgery typically costs $4,000 to $7,000, while advanced Mohs microsurgery runs from $1,800 to $3,200. Patients often find savings of 50–80% compared to the United States. Top treatment centers are located in Warsaw, Krakow, and Wieliszew.
Typical Melanoma Treatment Costs in Poland
Bookimed Expert Insight: Patients seeking high-precision treatment for complex cases should consider the Institute of Cybernetic Surgery Cyberknife. This center is unique in Poland for its CyberKnife technology and was developed through European Regional Development Fund grants. For those requiring integrated care, Warsaw-based facilities like Medical Centre ENEL-MED and John Paul II Western Hospital offer multidisciplinary teams. These clinics provide international-level medical care with highly experienced Polish oncologists.
| Poland | Turkey | Austria | |
| Mohs microsurgery | from $1,800 | from $2,200 | from $4,000 |
| Melanoma surgery | from $4,000 | from $3,500 | from $9,500 |
| Actinium-225 Therapy | from $30,000 | from $22,955 | from $55,000 |
| Immunotherapy with Keytruda (Pembolizumab) | from $8,000 | from $3,300 | from $15,000 |
| Wide excision of melanoma | - | from $4,000 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Melanoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Melanoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Melanoma treatment journey.
The doctor specializes in delivering high-quality and precise treatments in the fields of microscopic endodontics and prosthetics.
Written by Veronika Kazina
Melanoma treatment in Poland centers on advanced surgical excision and modern systemic therapies. Primary options include wide local excision and Mohs microsurgery for localized lesions. Leading oncology facilities also offer immunotherapy with Pembrolizumab and specialized radiosurgery using CyberKnife technology for complex or metastatic cases.
Bookimed Expert Insight: Patient volume data suggests Poland is a primary hub for specialized oncology. Facilities like the Institute of Cybernetic Surgery Cyberknife offer unique access to radiosurgery. This clinic received European Regional Development Fund support for its innovative technology. Patients often choose Poland to bridge the gap between treatment quality and accessibility.
Patient Consensus: Patients note that private clinics offer significantly faster scheduling than public systems. They strongly recommend early genetic testing to confirm eligibility for modern immunotherapy protocols.
Not all modern melanoma drugs are reimbursed in Poland. While the Ministry of Health updates the List of Refunded Medicines periodically, access to new therapies often lags. Core immunotherapies like Nivolumab and Pembrolizumab are typically covered through specific National Drug Programs for advanced cases.
Bookimed Expert Insight: Our data from 3,440 requests shows Poland functions as a major oncology hub with 86 clinics. Facilities like the Institute of Cybernetic Surgery Cyberknife offer specialized technology like CyberKnife for precise tumor targeting. Patients often find better reimbursement success at these large, specialized centers in cities like Warsaw or Wieliszew compared to smaller regional hospitals.
Patient Consensus: Patients note that securing reimbursement often requires early genetic testing for BRAF or PD-L1 mutations. Many report significant bureaucratic hurdles and long appeal processes before getting access to modern drug programs.
Melanoma treatment in the Polish public system (NFZ) typically begins within 21 to 40 days for urgent cases. While general practitioners offer same-day appointments, specialized oncology care usually requires a fast-track DILO card. Diagnostic waits for MRIs average 58 days without priority status.
Bookimed Expert Insight: Poland holds a high global rank for medical tourism, sitting at 6th place in our network. This popularity is driven by specialized centers like the Institute of Cybernetic Surgery Cyberknife in Wieliszew. This unique facility utilizes advanced radiation technology not found in standard public regional hospitals. Patients often find that highly specialized centers maintain more efficient workflows than general public oncology departments.
Patient Consensus: Patients note that arriving with complete pathology reports and imaging helps bypass re-testing delays. Many recommend confirming an urgent classification with a GP to significantly shorten the surgery scheduling gap.
Recommended centers for specialized melanoma care include NCI-designated Comprehensive Cancer Centers and leading European oncology institutes. In Poland, Warsaw is the primary hub due to complex surgical capabilities. Top facilities offer multidisciplinary teams, CyberKnife radiation, and immunotherapy protocols like Pembrolizumab for advanced cases.
Bookimed Expert Insight: While many patients look for private clinics, the data shows that specialized centers like the Institute of Cybernetic Surgery in Wieliszew offer unique grants for innovative technology. Choosing a center with specific European Regional Development Fund recognition often signals higher investment in modern oncological equipment like CyberKnife. This can be a vital differentiator for patients needing alternatives to traditional surgery.
Patient Consensus: Patients note that traveling to Warsaw is often necessary to access the most experienced oncology departments. Many suggest getting a second opinion at university-affiliated hospitals before starting immunotherapy or major surgery.